Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer
Natacha Bordry,
Alfredo Addeo,
Cyril Jaksic,
Valérie Dutoit,
Pascale Roux-Lombard,
Dimpy P. Shah,
Pankil K. Shah,
Angèle Gayet-Ageron,
Alex Friedlaender,
Sébastien Bugeia,
Garance Gutknecht,
Anna Battagin,
Maragrazia Di Marco,
Pierre-Francois Simand,
Intidhar Ladibi-Galy,
Sarah Fertani,
José Sandoval,
Pierre-Yves Dietrich,
Nicolas Mach
Affiliations
Natacha Bordry
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
Alfredo Addeo
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland; Corresponding author
Cyril Jaksic
CRC& Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and Geneva University Hospital, Geneva, Switzerland
Valérie Dutoit
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
Pascale Roux-Lombard
Immunology and Allergology Laboratory, Geneva University Hospital, University of Geneva, 1205 Geneva, Switzerland
Dimpy P. Shah
Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
Pankil K. Shah
Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
Angèle Gayet-Ageron
CRC& Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and Geneva University Hospital, Geneva, Switzerland
Alex Friedlaender
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland; Oncology Department, University Hospital of Geneva, Switzerland, Clinique Générale Beaulieu, Geneva, Switzerland
Sébastien Bugeia
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
Garance Gutknecht
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
Anna Battagin
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
Maragrazia Di Marco
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
Pierre-Francois Simand
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
Intidhar Ladibi-Galy
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
Sarah Fertani
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
José Sandoval
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
Pierre-Yves Dietrich
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
Nicolas Mach
Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
Summary: Little is known on the long-lasting humoral response and the T cell activation induced by SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-CoV-2 mRNA vaccines through measuring the seroconversion rate at pre-specified time points and the effect on the T cell immunity in patients with cancers. The study included 131 adult patients with solid or hematological cancer, who received SARS-CoV-2 mRNA vaccines. 96.2% of them exhibited adequate antibody response to the SARS-CoV-2 mRNA vaccines 2 months after the booster dose. SARS-CoV-2 mRNA vaccines could induce T cell activation; however, this is more likely in patients who have a positive seroconversion (94%) compared with the patients who did not (50%). Further research into the clinical relevance of low antibodies titers and lack of T cell activity is required to set up an effective vaccination strategy within this group of patients.
